{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T17:08:51Z","timestamp":1783962531210,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T00:00:00Z","timestamp":1631923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T00:00:00Z","timestamp":1631923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s11845-021-02767-0","type":"journal-article","created":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T21:02:20Z","timestamp":1631998940000},"page":"1659-1665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical efficacy of fixed-dose radioactive iodine for the treatment of hyperthyroidism at a single centre: our experience"],"prefix":"10.1007","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3664-4890","authenticated-orcid":false,"given":"Dilip","family":"Nair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Maweni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoforos","family":"Constantinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivanthi","family":"Kandiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidhartha","family":"Nagala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theingi","family":"Aung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,18]]},"reference":[{"issue":"6","key":"2767_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1365-2265.1977.tb01340.x","volume":"7","author":"WM Tunbridge","year":"1977","unstructured":"Tunbridge WM, Evered DC, Hall R et al (1977) The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 7(6):481\u2013493. https:\/\/doi.org\/10.1111\/j.1365-2265.1977.tb01340.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2767_CR2","unstructured":"UK Guidelines for the Use of Thyroid Function Tests (2006) https:\/\/www.british-thyroid-association.org\/sandbox\/bta2016\/uk_guidelines_for_the_use_of_thyroid_function_tests.pdf. Accessed July 2006"},{"key":"2767_CR3","doi-asserted-by":"publisher","unstructured":"Abraham P, Avenell A, McGeoch SC et al (2010) Antithyroid drug regimen for treating Graves\u2019 hyperthyroidism. Cochrane Database Syst Rev 2010 (1):Cd003420.\u00a0https:\/\/doi.org\/10.1002\/14651858.CD003420.pub4","DOI":"10.1002\/14651858.CD003420.pub4"},{"issue":"11","key":"2767_CR4","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1089\/thy.2005.15.1279","volume":"15","author":"M Abraham-Nordling","year":"2005","unstructured":"Abraham-Nordling M, T\u00f6rring O, Hamberger B et al (2005) Graves\u2019 disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid 15(11):1279\u20131286. https:\/\/doi.org\/10.1089\/thy.2005.15.1279","journal-title":"Thyroid"},{"issue":"6","key":"2767_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1089\/thy.2010.0417","volume":"21","author":"RS Bahn Chair","year":"2011","unstructured":"Bahn Chair RS, Burch HB, Cooper DS et al (2011) Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21(6):593\u2013646. https:\/\/doi.org\/10.1089\/thy.2010.0417","journal-title":"Thyroid"},{"issue":"9","key":"2767_CR6","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1210\/jc.2003-031223","volume":"89","author":"CH Read Jr","year":"2004","unstructured":"Read CH Jr, Tansey MJ, Menda Y (2004) A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves\u2019 patients. J Clin Endocrinol Metab 89(9):4229\u20134233. https:\/\/doi.org\/10.1210\/jc.2003-031223","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2767_CR7","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS et al (2016) American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26(10):1343\u20131421. https:\/\/doi.org\/10.1089\/thy.2016.0229","journal-title":"Thyroid"},{"issue":"10","key":"2767_CR8","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40618-016-0505-x","volume":"39","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Chiovato L, Vitti P (2016) Management of hyperthyroidism due to Graves\u2019 disease: frequently asked questions and answers (if any). J Endocrinol Invest 39(10):1105\u20131114. https:\/\/doi.org\/10.1007\/s40618-016-0505-x","journal-title":"J Endocrinol Invest"},{"issue":"1064","key":"2767_CR9","doi-asserted-by":"publisher","first-page":"20160418","DOI":"10.1259\/bjr.20160418","volume":"89","author":"J Wang","year":"2016","unstructured":"Wang J, Qin L (2016) Radioiodine therapy versus antithyroid drugs in Graves\u2019 disease: a meta-analysis of randomized controlled trials. Br J Radiol 89(1064):20160418. https:\/\/doi.org\/10.1259\/bjr.20160418","journal-title":"Br J Radiol"},{"key":"2767_CR10","unstructured":"Excellence NIoHaC (2019) Thyroid disease: assessment and management. https:\/\/www.nice.org.uk\/guidance\/NG145."},{"key":"2767_CR11","doi-asserted-by":"publisher","unstructured":"T\u00f6rring O, Tallstedt L, Wallin G et al (1996) Graves\u2019 hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab 81 (8):2986\u20132993. https:\/\/doi.org\/10.1210\/jcem.81.8.8768863","DOI":"10.1210\/jcem.81.8.8768863"},{"key":"2767_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40842-018-0071-6","volume":"4","author":"KK Wong","year":"2018","unstructured":"Wong KK, Shulkin BL, Gross MD, Avram AM (2018) Efficacy of radioactive iodine treatment of Graves\u2019 hyperthyroidism using a single calculated (131) I dose. Clin Diabetes Endocrinol 4:20. https:\/\/doi.org\/10.1186\/s40842-018-0071-6","journal-title":"Clin Diabetes Endocrinol"},{"issue":"2","key":"2767_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4103\/1450-1147.167584","volume":"15","author":"A Kartamihardja","year":"2016","unstructured":"Kartamihardja A, Massora S (2016) The influence of antithyroid drug discontinuation to the therapeutic efficacy of <sup>131<\/sup> I in hyperthyroidism. World Journal of Nuclear Medicine 15(2):81\u201384. https:\/\/doi.org\/10.4103\/1450-1147.167584","journal-title":"World Journal of Nuclear Medicine"},{"key":"2767_CR14","unstructured":"Thyroid disease: assessment and management. [I] Management of thyrotoxicosis: -drugs vs surgery vs radioactive iodine-safety of treatment with radioactive iodine. (2019). https:\/\/www.nice.org.uk\/guidance\/ng145\/evidence\/i-management-of-thyrotoxicosis-drugs-vs-surgery-vs-radioactive-iodine-safety-of-treatment-with-radioactive-iodine-pdf-6967421685."},{"issue":"5","key":"2767_CR15","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1365-2265.2004.02152.x","volume":"61","author":"S Metso","year":"2004","unstructured":"Metso S, Jaatinen P, Huhtala H et al (2004) Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol (Oxf) 61(5):641\u2013648. https:\/\/doi.org\/10.1111\/j.1365-2265.2004.02152.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"2767_CR16","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1007\/bf03344157","volume":"29","author":"B Tarantini","year":"2006","unstructured":"Tarantini B, Ciuoli C, Di Cairano G et al (2006) Effectiveness of radioiodine (131-I) as definitive therapy in patients with autoimmune and non-autoimmune hyperthyroidism. J Endocrinol Invest 29(7):594\u2013598. https:\/\/doi.org\/10.1007\/bf03344157","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2767_CR17","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1530\/eje-09-0286","volume":"161","author":"A de Rooij","year":"2009","unstructured":"de Rooij A, Vandenbroucke JP, Smit JW et al (2009) Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. Eur J Endocrinol 161(5):771\u2013777. https:\/\/doi.org\/10.1530\/eje-09-0286","journal-title":"Eur J Endocrinol"},{"key":"2767_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/tcrm.s5229","volume":"6","author":"P Abraham","year":"2010","unstructured":"Abraham P, Acharya S (2010) Current and emerging treatment options for Graves\u2019 hyperthyroidism. Ther Clin Risk Manag 6:29\u201340. https:\/\/doi.org\/10.2147\/tcrm.s5229","journal-title":"Ther Clin Risk Manag"},{"key":"2767_CR19","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1097\/01.rlu.0000242213.26839.20","volume":"31","author":"V Vijayakumar","year":"2006","unstructured":"Vijayakumar V, Ali S, Nishino T, Nusynowitz M (2006) What influences early hypothyroidism after radioiodine treatment for Graves\u2019 hyperthyroidism? Clin Nucl Med 31:688\u2013689","journal-title":"Clin Nucl Med"},{"issue":"4","key":"2767_CR20","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/maj.0000000000000288","volume":"348","author":"M Liu","year":"2014","unstructured":"Liu M, Jing D, Hu J, Yin S (2014) Predictive factors of outcomes in personalized radioactive iodine ((131)I) treatment for Graves\u2019 disease. Am J Med Sci 348(4):288\u2013293. https:\/\/doi.org\/10.1097\/maj.0000000000000288","journal-title":"Am J Med Sci"},{"issue":"12","key":"2767_CR21","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s40618-018-0918-9","volume":"41","author":"E Masiello","year":"2018","unstructured":"Masiello E, Veronesi G, Gallo D et al (2018) Antithyroid drug treatment for Graves\u2019 disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Invest 41(12):1425\u20131432. https:\/\/doi.org\/10.1007\/s40618-018-0918-9","journal-title":"J Endocrinol Invest"},{"key":"2767_CR22","doi-asserted-by":"publisher","unstructured":"Aung A, Zammitt N, Dover A\u00a0 et al (2018) Predicting outcomes and complications following radioiodine therapy in Graves\u2019 thyrotoxicosis Clin Endocrinol 90 https:\/\/doi.org\/10.1111\/cen.13873","DOI":"10.1111\/cen.13873"},{"issue":"1","key":"2767_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1385\/endo:25:1:55","volume":"25","author":"C Erem","year":"2004","unstructured":"Erem C, Kandemir N, Hacihasanoglu A et al (2004) Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome. Endocrine 25(1):55\u201360. https:\/\/doi.org\/10.1385\/endo:25:1:55","journal-title":"Endocrine"},{"key":"2767_CR24","unstructured":"Ghadban WK, Zirie MA, Al-Khateeb DA et al (2003) Radioiodine treatment of hyperthyroidism. Success rate and influence of thyrostatic medication. Saudi Med J 24(4):347\u2013351"},{"key":"2767_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3329\/bjnm.v19i1.35568","volume":"19","author":"K Nahar","year":"2018","unstructured":"Nahar K, Akhter P (2018) Factors affecting and outcome of radioactive iodine therapy in hyperthyroidism: a study at Institute of Nuclear Medicine & Allied Sciences (INMAS). Sylhet Bangladesh J Nucl Med 19:19. https:\/\/doi.org\/10.3329\/bjnm.v19i1.35568","journal-title":"Sylhet Bangladesh Journal of Nuclear Medicine"},{"issue":"6","key":"2767_CR26","doi-asserted-by":"publisher","first-page":"181","DOI":"10.47102\/annals-acadmedsg.V48N6p181","volume":"48","author":"WL Tay","year":"2019","unstructured":"Tay WL, Chng CL, Tien CS et al (2019) High thyroid stimulating receptor antibody titre and large goitre size at first-time radioactive iodine treatment are associated with treatment failure in Graves\u2019 disease. Ann Acad Med Singap 48(6):181\u2013187","journal-title":"Ann Acad Med Singap"},{"issue":"3","key":"2767_CR27","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/mnm.0000000000001138","volume":"41","author":"H Park","year":"2020","unstructured":"Park H, Kim HI, Park J et al (2020) The success rate of radioactive iodine therapy for Graves\u2019 disease in iodine-replete area and affecting factors: a single-center study. Nucl Med Commun 41(3):212\u2013218. https:\/\/doi.org\/10.1097\/mnm.0000000000001138","journal-title":"Nucl Med Commun"},{"issue":"4","key":"2767_CR28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1530\/eje-16-0986","volume":"176","author":"T Struja","year":"2017","unstructured":"Struja T, Kaeslin M, Boesiger F et al (2017) External validation of the GREAT score to predict relapse risk in Graves\u2019 disease: results from a multicenter, retrospective study with 741 patients. Eur J Endocrinol 176(4):413\u2013419. https:\/\/doi.org\/10.1530\/eje-16-0986","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2767_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/cen.14301","volume":"94","author":"L Lu","year":"2021","unstructured":"Lu L, Gao C, Zhang N (2021) Age moderates the associations between TRAbs, free T3 and outcomes of Graves\u2019 disease patients with radioactive iodine treatment. Clin Endocrinol (Oxf) 94(2):303\u2013309. https:\/\/doi.org\/10.1111\/cen.14301","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"2767_CR30","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1089\/thy.2005.15.1047","volume":"15","author":"B Quadbeck","year":"2005","unstructured":"Quadbeck B, Hoermann R, Roggenbuck U et al (2005) Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves\u2019 disease. Thyroid 15(9):1047\u20131054. https:\/\/doi.org\/10.1089\/thy.2005.15.1047","journal-title":"Thyroid"},{"issue":"4","key":"2767_CR31","doi-asserted-by":"publisher","first-page":"e1006","DOI":"10.1210\/clinem\/dgz292","volume":"105","author":"GJ Kahaly","year":"2019","unstructured":"Kahaly GJ, Diana T, Kanitz M et al (2019) Prospective trial of functional thyrotropin receptor antibodies in Graves disease. J Clin Endocrinol Metab 105(4):e1006\u2013e1014. https:\/\/doi.org\/10.1210\/clinem\/dgz292","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-021-02767-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-021-02767-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-021-02767-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T02:08:45Z","timestamp":1658628525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-021-02767-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,18]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["2767"],"URL":"https:\/\/doi.org\/10.1007\/s11845-021-02767-0","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,18]]},"assertion":[{"value":"13 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}